CompletedPhase 3NCT03422653
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frédérique Menzaghi, PhD, DDSCara Therapeutics
- Intervention
- CR845 0.5 mcg/kg(drug)
- Enrollment
- 378 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2020
Study locations (30)
- Cara Therapeutics Study Site, Homewood, Alabama, United States
- Cara Therapeutics Study Site, Huntsville, Alabama, United States
- Cara Therapeutics Study Site, Bakersfield, California, United States
- Cara Therapeutics Study Site 2, Beverly Hills, California, United States
- Cara Therapeutics Study Site, Beverly Hills, California, United States
- Cara Therapeutics Study Site, Chula Vista, California, United States
- Cara Therapeutics Study Site, Corona, California, United States
- Cara Therapeutics Study Site, Escondido, California, United States
- Cara Therapeutics Study Site, Fountain Valley, California, United States
- Cara Therapeutics, La Mesa, California, United States
- Cara Therapeutics Study Site, Long Beach, California, United States
- Cara Therapeutics Study Site, Ontario, California, United States
- Cara Therapeutics Study Site, Riverside, California, United States
- Cara Therapeutics Study Site, Roseville, California, United States
- Cara Therapeutics Study Site, San Diego, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03422653 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.